Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Teva paid 40 billion for allergans generic business
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Craigbadon Oct 13, 2016 10:40pm
67 Views
Post# 25342154

RE:RE:RE:Teva paid 40 billion for allergans generic business

RE:RE:RE:Teva paid 40 billion for allergans generic businessIn fairness he didn't say $80 per share, he said $80US per share! Lol
I just hope he didn't scare any hard working, innocent shorts into covering.

LaticelnExile wrote:
Craigbad wrote:
fundtrader wrote:
lots of money in generics..i guess cxr is worth close to 10 billion then or 80$ us a share


Oh this one is Pure Platinum.   


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities